CME in Minutes: Education in Gastroenterology

Please visit answersincme.com/FSP860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Jay N. Yepuri, MD, MS, FACG, FTSGE. In this activity, an expert in gastroenterology discusses molecular prognostics tests that predict the risk of progression from Barrett’s esophagus (BE) to esophageal adenocarcinoma (EAC). Upon completion of this activity, participants should be better able to: Describe the limitations of traditional approaches to predicting risk of progression to EAC for patients with BE; Review the evolving role of advanced molecular prognostic tests in assessing risk of progression to EAC in patients with BE; and Outline multidisciplinary strategies to integrate advanced molecular prognostic tests into the management of patients with BE.

Please visit answersincme.com/NHB860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Zev Wainberg, MD. In this activity, an expert in oncology discusses the use of TROP2-directed antibody-drug conjugates (ADCs) across solid tumors. Upon completion of this activity, participants should be better able to: Review the rationale for targeting TROP2 with antibody-drug conjugates (ADCs) across tumor stages and settings; Evaluate the clinical profiles of available and emerging TROP-targeting ADCs across tumor stages and settings; and Apply evidence-based strategies to recognize and monitor treatment-related adverse events (TRAEs) associated with ADCs.

Please visit answersincme.com/AQE860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Nirmala Gonsalves, MD, AGAF, FACG. In this activity, an expert in esophageal gastroenterology, discusses strategies for pharmacological treatment of eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Specify the current guideline recommendations for the pharmacologic treatment of eosinophilic esophagitis (EoE); Formulate personalized strategies to use approved pharmacologic options during initiation and maintenance phases of EoE management; and Apply multidisciplinary strategies to optimize long-term management of patients with EoE using approved pharmacologic treatments.

Please visit answersincme.com/860/103518989-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD and Chiara Cremolini, MD, PhD. In this activity, experts in metastatic colorectal cancer (mCRC) discuss real-world evidence and clinical insights related to durable responses and long-term benefits in later-line care. Upon completion of this activity, participants should be better able to: Propose treatment plans based on predictors of durable benefit and real-world evidence.

Please visit answersincme.com/860/102331945-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth Smyth, MD, FRCP and Daniela Molena, MD. In this activity, experts in gastric/gastroesophageal junction adenocarcinoma discuss the latest evidence and practical strategies for optimizing the treatment of resectable gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma with perioperative immunotherapy. Upon completion of this activity, participants should be better able to: Evaluate the evidence supporting the integration of perioperative immunotherapy (IO) in the treatment of resectable gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma; Analyze the role of biomarkers in decision-making for perioperative IO in resectable G/GEJ adenocarcinoma; and Outline multidisciplinary strategies for optimizing the care of patients receiving perioperative IO for resectable G/GEJ adenocarcinoma.

Please visit answersincme.com/ZPW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by David R. Staskin, MD. In this activity, an expert in urology discusses strategies to diagnose and individualize treatment for overactive bladder (OAB) in patients with benign prostatic hyperplasia (BPH), including the role of beta-3 adrenergic agonists and guideline-based care. Upon completion of this activity, participants should be better able to: Identify strategies to diagnose overactive bladder (OAB) in patients with benign prostatic hyperplasia (BPH); Assess the evidence for beta-3 adrenergic agonists in the treatment of OAB among patients with BPH; and Outline approaches to tailor OAB treatment for individual patients with BPH.

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Please visit answersincme.com/860/103518989-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD and Tanios Bekaii-Saab, MD. In this activity, experts in metastatic colorectal cancer (mCRC) discuss proactive toxicity management and dose optimization strategies to help patients remain on treatment and improve outcomes. Upon completion of this activity, participants should be better able to: Integrate proactive management strategies to maintain patients on later-line therapy.

Please visit answersincme.com/860/103518989-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD; and Daniel Ahn, DO, MS. In this activity, experts in metastatic colorectal cancer (mCRC) discuss strategies for sequencing later-line therapies and planning treatment pathways to preserve future options. Upon completion of this series, participants should be better able to: Apply evidence-based strategies for later-line treatment selection in mCRC; Integrate proactive management strategies to maintain patients on later-line therapy; and Propose treatment plans based on predictors of durable benefit and real-world evidence.

Please visit answersincme.com/860/MED-GST-04054-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Joy W. Chang, MD, MS; Robbie Pesek, MD; and Sarah Enslin, PA-C, MS. In this activity, multidisciplinary experts in pediatric and adult eosinophilic esophagitis (EoE) highlight updated management guidelines and provide case-based insights on implementing guideline-concordant pharmacologic therapies in real-world practice. Upon completion of this activity, participants should be better able to: Identify current guideline recommendations for the pharmacologic treatment of EoE; Specify how patient, disease, and treatment factors impact treatment selection for EoE; and Integrate guideline-recommended pharmacologic therapies into individualized care for patients with EoE. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/CKX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prithviraj Bose, MD. In this activity, an expert in hematology discusses the role of current and emerging treatment options for patients living with advanced systemic mastocytosis. Upon completion of this activity, participants should be better able to: Identify prognostic features of advanced systemic mastocytosis (AdvSM) that guide diagnosis and care planning; Describe current and emerging treatment options for patients with AdvSM; and Evaluate patient- and disease-related strategies that inform treatment selection in AdvSM.

Please visit answersincme.com/860/MED-GST-03630-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Evan S. Dellon, MD, MPH; and Shauna Schroeder, MS, MD. In this activity, experts in managing eosinophilic esophagitis (EoE) engage in a case-based discussion of current EoE guidelines, key diagnostic pearls for pediatric and adult patients, and clinical factors driving individualized treatment decisions. Upon completion of this activity, participants should be better able to: Review updated clinical guidelines for the diagnosis and management of EoE; Identify differences in symptom presentation between pediatric and adult patients with EoE; and Specify patient, disease, and treatment factors that influence selection and adjustment of EoE therapy.

Please visit answersincme.com/ZTY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Daniel J. DeAngelo, MD, PhD. In this activity, an expert in hematology discusses targeted treatment options for the management of indolent systemic mastocytosis. Upon completion of this activity, participants should be better able to: Recognize the impacts of indolent systemic mastocytosis (ISM) on patients’ quality of life; Discuss the clinical significance of selective KIT D816V–targeting tyrosine kinase inhibitors (TKIs) in the management of patients with ISM; and Design patient-centered strategies for integrating selective KIT D816V–targeting TKIs into the management of ISM.

Please visit answersincme.com/QSK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Markus Cornberg, MD. In this activity, an expert in infectious diseases discusses the management of patients with hepatitis C virus (HCV) infection. Upon completion of this activity, participants should be better able to: Discuss the factors influencing timely intervention in hepatitis C virus (HCV) management; Describe recommended HCV screening strategies to increase uptake in underserved populations; and Recognize appropriate criteria for initiating simplified HCV therapy or referring patients for specialist care.

Please visit answersincme.com/KQK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Virginia Clark, MD, MS. In this activity, an expert in liver disease discusses practical considerations for identifying and managing liver disease related to alpha-1 antitrypsin deficiency (AATD) across the care continuum. Upon completion of this activity, participants should be better able to: Apply strategies to reach a diagnosis of AATD and associated liver disease; Summarize the evolving treatment landscape for AATD-associated liver disease; and Explain multidisciplinary team approaches to effectively manage patients with AATD-associated liver disease.

Please visit answersincme.com/TDB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in colorectal cancer discusses optimizing care with immunotherapy for patients with MSI-H/dMMR disease. Upon completion of this activity, participants should be better able to: Discuss the efficacy and safety of immunotherapy-based regimens in patients with microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) advanced colorectal cancer (CRC); and Outline evidence-based strategies to optimize outcomes for patients with MSI-H/dMMR advanced CRC.

Please visit answersincme.com/WTR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hepatology and endocrinology discuss the impact of obesity on liver disease progression, current and emerging GLP-1 receptor agonist therapies, and strategies to optimize clinical outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Upon completion of this activity, participants should be better able to: Identify how obesity impacts metabolic dysfunction–associated steatohepatitis (MASH) progression and liver health; Review current and emerging glucagon-like peptide-1 (GLP-1) receptor agonist (RA)–based therapies for the treatment of MASH; and Outline approaches to optimize patient outcomes in obesity-related liver disease.

Please visit answersincme.com/KTK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancers discusses strategies for treatment of patients with colorectal cancer using tyrosine kinase inhibitors. Upon completion of this activity, participants should be better able to: Identify patients with metastatic colorectal cancer (mCRC) who are suitable for tyrosine kinase inhibitor (TKI) treatment; Outline practical, patient-centered strategies to maximize quality of life in patients receiving later-line TKI treatment for mCRC; and Review approaches to manage adverse events associated with later-line TKI treatment for mCRC.

Please visit answersincme.com/DDP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human epidermal growth factor receptor 3 (HER3)–directed antibody–drug conjugates (ADCs) for the treatment of patients with advanced solid tumors. Upon completion of this activity, participants should be better able to: Explain the rationale for the pan-tumor use of HER3-directed treatment for patients with locally advanced or metastatic solid tumors; Review clinical trials of investigational HER3-directed ADCs in previously treated patients with advanced solid tumors; and Outline criteria that may guide the selection of HER3-directed ADCs to treat advanced solid tumors, based on available evidence.

Please visit answersincme.com/URZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in esophageal carcinoma (EAC) discusses novel tests to predict the risk of progression from Barrett’s esophagus (BE) to EAC. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using novel prognostic stratification tests to predict the risk of progression from BE to EAC, Review the clinical support for prognostic tests that provide actionable information for identifying patients with BE who are at risk of progression to EAC; and Outline strategies to integrate novel prognostic tests into the surveillance algorithm for patients with BE who may be at risk of progression to EAC.